MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma

Filipska, Martyna; Skrzypski, Marcin; Czetyrbok, Katarzyna; Stokowy, Tomasz; Stasiłojć, Grzegorz; Supernat, Anna; Jassem, Jacek; Żaczek, Anna; Bigda, Jacek

doi:10.1016/j.lungcan.2018.02.002

Cited by 36 publications

(25 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-19a was found to be upregulated and promote development of NPC via targeting TGFβR2 [23]. Similarly, upregulation of miR-192 was also found in esophageal squamous cell carcinoma and squamous cell lung carcinoma [24,25]. Moreover, miR-192 was upregulated in type 1 diabetes mellitus, regulated pancreatic β cell development, and inhibited insulin secretion through suppressing GLP-1 expression [26].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway

Huang

Hou²,

Zhu

et al. 2020

World J Surg Onc

View full text Add to dashboard Cite

Background: The dysregulation of microRNAs (miRNAs) has been found in diseases and cancers, including microRNA-192 (miR-192). This study was designed to investigate the role of miR-192 in nasopharyngeal carcinoma (NPC) progression. Methods: The expression levels of miR-192 and some genes were assessed by qRT-PCR and Western blot. The function of miR-192 was investigated through MTT, Transwell, and dual-luciferase reporter assays. Results: The expression of miR-192 was increased in NPC tissues, and high miR-192 expression predicted poor prognosis in NPC patients. Functionally, upregulation of miR-192 promoted NPC cell migration, invasion, and growth. Furthermore, miR-192 activated EMT and PI3K/AKT pathway to regulate NPC progression. In addition, miR-192 directly targeted RB1 and suppressed its expression in NPC. Moreover, overexpression of RB1 weakened the promoted effect of miR-192 in NPC. Conclusion: miR-192 promoted cell viability and metastasis in NPC through suppressing RB1 expression and activating PI3K/AKT pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway

Huang

Hou²,

Zhu

et al. 2020

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Another miRNA, whose participation in different types of human tumors has been well-established in numerous studies is miR-192 (28)(29)(30). Notably, in the present study, we found that the expression of miR-192 was significantly decreased only in the breast cancer tissues, but not in the serum.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of microRNA‑9 and ‑192 expression levels as biomarkers in patients suffering from breast cancer

et al. 2019

View full text Add to dashboard Cite

Given the global outbreak of breast cancer and its debilitating effect on women's health, it is not surprising that tremendous efforts have been made with an aim of shedding more light on the mechanisms involved in the pathogenesis of this type of cancer. Among the long list of risk factors associated with this malignancy, recently, the role of microRNAs (miRNAs or miRs) has turned into a hotspot for breast cancer investigations. miRNAs approximately 20 nucleotides in length and are located in either an exon or an intron, playing a role in the regulation of gene expression. In the present study, we extracted RNA from both the serum and cancerous tissue of breast cancer patients and after synthesizing the cDNA, we performed quantitative PCR to determine the expression levels of miR-9 and miR-192. The resulting data revealed that while the mRNA expression level of miR-9 was significantly decreased in the breast cancer tissues, there was no noticeable change in the expression level of this miRNA in the serum samples. Likewise, we found that the marked downregulation of miR-192 was only restricted to the cancerous tissues, but was not found in the serum of patients. Based on the meaningful downregulation of the expression of miR-9 and miR-192, this study provides a plausible framework for these miRNAs as effective biomarkers for breast cancer patients.

show abstract

“…We identified 9 cancer types associated with dysregulated gene methylation in AA race: bladder urothelial carcinoma (30 genes), BRCA (325 genes), colon adenocarcinoma (294 genes), esophageal carcinoma (541 genes), head and neck carcinoma (204 genes), KIRC (263 genes), PRAD (269 genes), THCA (482 genes), and UCEC (157 genes) (see Supporting Table 6). These alterations are known to elicit resistance to chemotherapy [38][39][40][41] and constitute potential therapeutic targets. 2B).…”

Section: Dna Methylationmentioning

confidence: 99%

“…Among 7 of 8 cancer types, we identified hypomethylation of TRPC5 (transient receptor potential channel C5), S100A14 (S100 calcium binding protein A14), and MIR662 in AA tumors compared with EA tumors, leading to increased gene expression. These alterations are known to elicit resistance to chemotherapy [38][39][40][41] and constitute potential therapeutic targets. In addition, we observed that esophageal carcinoma tumors presented distinct sets of DNA methylation compared with other cancer types, with 466 of 541 unique genes (86%) affected.…”

Section: Dna Methylationmentioning

confidence: 99%

Pan‐cancer clinical and molecular analysis of racial disparities

Lara

Wang

Asare

et al. 2019

Cancer

View full text Add to dashboard Cite

Background Racial disparities in cancer outcomes are increasingly recognized, but comprehensive analyses, including molecular studies, are limited. The objective of the current study was to perform a pan‐cancer clinical and epigenetic molecular analysis of outcomes in African American (AA) and European American (EA) patients. Methods Cross‐platform analyses using cancer databases (the Surveillance, Epidemiology, and End Results program database and the National Cancer Data Base) and a molecular database (The Cancer Genome Ancestry Atlas) were performed to evaluate clinical and epigenetic molecular differences between AA and EA patients based on genetic ancestry. Results In the primary pan‐cancer survival analysis using the Surveillance, Epidemiology, and End Results database (2,045,839 patients; 87.5% EA and 12.5% AA), AA patients had higher mortality rates for 28 of 42 cancer types analyzed (hazard ratio, >1.0). AAs continued to have higher mortality in 13 cancer types after adjustment for socioeconomic variables using the National Cancer Database (5,150,023 patients; 11.6% AA and 88.4% EA). Then, molecular features of 5,283 tumors were analyzed in patients who had genetic ancestry data available (87.2% EA and 12.8% AA). Genes were identified with altered DNA methylation along with increased microRNA expression levels unique to AA patients that are associated with cancer drug resistance. Increased miRNAs (miR‐15a, miR‐17, miR‐130‐3p, miR‐181a) were noted in common among AAs with breast, kidney, thyroid, or prostate carcinomas. Conclusions The current results identified epigenetic features in AA patients who have cancer that may contribute to higher mortality rates compared with EA patients who have cancer. Therefore, a focus on molecular signatures unique to AAs may identify actionable molecular abnormalities.

show abstract

MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma

Cited by 36 publications

References 65 publications

MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway

MicroRNA-192 promotes the development of nasopharyngeal carcinoma through targeting RB1 and activating PI3K/AKT pathway

Evaluation of microRNA‑9 and ‑192 expression levels as biomarkers in patients suffering from breast cancer

Pan‐cancer clinical and molecular analysis of racial disparities

Contact Info

Product

Resources

About